Acral Necrosis in a COVID-19-Infected Man Treated with Botulinum Toxin Type A

Mette Soelberg Schjødt; Rikke Bech; Anne Braae Olesen

doi:10.1159/000520589

Acral Necrosis in a COVID-19-Infected Man Treated with Botulinum Toxin Type A

Mette Soelberg Schjødt^*, Rikke Bech, Anne Braae Olesen

^*Corresponding author for this work

Department of Clinical Medicine - The Department of Dermatology and Venereology

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Abstract

COVID-19 has been associated with acral ischemia and digital necrosis. Standard treatment of acral ischemia and digital or acral necrosis includes ongoing therapy with vasodilators and anticoagulants. However, these treatments are not always efficient to avoid the progression of necroses, which in the worst case can lead to amputation. Here, we report a case in which interdigital Botox® (botulinum toxin type A) nerve cord injection stopped the progression of acral necroses arising from an underlying vasculopathy due to COVID-19. Moreover, Botox® injection eliminated inflammation in the affected acral area within 2 weeks. This is the first case report to suggest Botox® injection as a new and improving treatment for acral necroses due to COVID-19.

Original language	English
Journal	Case Reports in Dermatology
Volume	13
Issue	3
Pages (from-to)	568-573
Number of pages	6
ISSN	1662-6567
DOIs	https://doi.org/10.1159/000520589
Publication status	Published - Dec 2021

Keywords

Acral necrosis
Botulinum toxin type A
COVID-19

Access to Document

10.1159/000520589Licence: CC BY-NC

Cite this

@article{9991b79e911b473bae93477138c9a603,

title = "Acral Necrosis in a COVID-19-Infected Man Treated with Botulinum Toxin Type A",

abstract = "COVID-19 has been associated with acral ischemia and digital necrosis. Standard treatment of acral ischemia and digital or acral necrosis includes ongoing therapy with vasodilators and anticoagulants. However, these treatments are not always efficient to avoid the progression of necroses, which in the worst case can lead to amputation. Here, we report a case in which interdigital Botox{\textregistered} (botulinum toxin type A) nerve cord injection stopped the progression of acral necroses arising from an underlying vasculopathy due to COVID-19. Moreover, Botox{\textregistered} injection eliminated inflammation in the affected acral area within 2 weeks. This is the first case report to suggest Botox{\textregistered} injection as a new and improving treatment for acral necroses due to COVID-19. ",

keywords = "Acral necrosis, Botulinum toxin type A, COVID-19",

author = "Schj{\o}dt, {Mette Soelberg} and Rikke Bech and {Braae Olesen}, Anne",

note = "Publisher Copyright: {\textcopyright} 2021 2021 The Author(s).",

year = "2021",

month = dec,

doi = "10.1159/000520589",

language = "English",

volume = "13",

pages = "568--573",

journal = "Case Reports in Dermatology",

issn = "1662-6567",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - Acral Necrosis in a COVID-19-Infected Man Treated with Botulinum Toxin Type A

AU - Schjødt, Mette Soelberg

AU - Bech, Rikke

AU - Braae Olesen, Anne

PY - 2021/12

Y1 - 2021/12

N2 - COVID-19 has been associated with acral ischemia and digital necrosis. Standard treatment of acral ischemia and digital or acral necrosis includes ongoing therapy with vasodilators and anticoagulants. However, these treatments are not always efficient to avoid the progression of necroses, which in the worst case can lead to amputation. Here, we report a case in which interdigital Botox® (botulinum toxin type A) nerve cord injection stopped the progression of acral necroses arising from an underlying vasculopathy due to COVID-19. Moreover, Botox® injection eliminated inflammation in the affected acral area within 2 weeks. This is the first case report to suggest Botox® injection as a new and improving treatment for acral necroses due to COVID-19.

AB - COVID-19 has been associated with acral ischemia and digital necrosis. Standard treatment of acral ischemia and digital or acral necrosis includes ongoing therapy with vasodilators and anticoagulants. However, these treatments are not always efficient to avoid the progression of necroses, which in the worst case can lead to amputation. Here, we report a case in which interdigital Botox® (botulinum toxin type A) nerve cord injection stopped the progression of acral necroses arising from an underlying vasculopathy due to COVID-19. Moreover, Botox® injection eliminated inflammation in the affected acral area within 2 weeks. This is the first case report to suggest Botox® injection as a new and improving treatment for acral necroses due to COVID-19.

KW - Acral necrosis

KW - Botulinum toxin type A

KW - COVID-19

UR - http://www.scopus.com/inward/record.url?scp=85122319321&partnerID=8YFLogxK

U2 - 10.1159/000520589

DO - 10.1159/000520589

M3 - Journal article

C2 - 35111009

AN - SCOPUS:85122319321

SN - 1662-6567

VL - 13

SP - 568

EP - 573

JO - Case Reports in Dermatology

JF - Case Reports in Dermatology

IS - 3

ER -

Acral Necrosis in a COVID-19-Infected Man Treated with Botulinum Toxin Type A

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this